HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazufumi Nakamura Selected Research

voglibose (Basen)

1/2022Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.
1/2020Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
1/2019The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
6/2015Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
7/2014DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazufumi Nakamura Research Topics

Disease

17Heart Failure
03/2022 - 06/2002
16Pulmonary Arterial Hypertension
01/2021 - 12/2009
11Coronary Artery Disease (Coronary Atherosclerosis)
04/2019 - 05/2011
11Familial Primary Pulmonary Hypertension
07/2013 - 09/2004
9Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 07/2006
9Pulmonary Hypertension
01/2021 - 11/2004
9Brugada Syndrome
12/2017 - 06/2002
8Atherosclerosis
01/2022 - 07/2004
8Hypertension (High Blood Pressure)
11/2021 - 09/2004
7Atrial Fibrillation
11/2021 - 01/2003
7Inflammation (Inflammations)
10/2018 - 01/2003
6Cardiac Arrhythmias (Arrythmia)
12/2021 - 11/2003
6Left Ventricular Dysfunction
01/2021 - 11/2008
6Hypertrophy
05/2019 - 08/2011
6Body Weight (Weight, Body)
05/2019 - 06/2002
6Ventricular Fibrillation
05/2019 - 01/2008
6Sarcoidosis (Schaumann Disease)
10/2018 - 10/2007
5Myocardial Infarction
02/2022 - 11/2011
5Type 2 Diabetes Mellitus (MODY)
02/2022 - 07/2014
5Fibrosis (Cirrhosis)
01/2021 - 02/2014
5Cardiomyopathies (Cardiomyopathy)
01/2021 - 01/2005
5Chronic Renal Insufficiency
09/2018 - 01/2011
5Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
08/2017 - 06/2002
5Long QT Syndrome
06/2017 - 02/2003
4Insulin Resistance
03/2022 - 04/2014
4Amyloidosis
12/2021 - 12/2019
4Cardiomegaly (Heart Hypertrophy)
05/2019 - 12/2003
4Hemorrhage
04/2019 - 02/2005
4Ventricular Tachycardia
08/2017 - 11/2003
4Ischemia
06/2017 - 11/2011
4Hyperlipidemias (Hyperlipidemia)
04/2016 - 08/2011
3Myocardial Ischemia (Ischemic Heart Diseases)
03/2022 - 06/2005
3Diabetes Mellitus
01/2022 - 06/2018
3Hypercholesterolemia
01/2022 - 01/2018
3Cardiotoxicity
01/2022 - 01/2021
3Stable Angina
02/2021 - 03/2014
3Myocarditis (Carditis)
01/2021 - 01/2021
3Heart Diseases (Heart Disease)
01/2021 - 07/2013
3Infections
08/2019 - 02/2018
3Shock
08/2017 - 11/2010
3Hypoxia (Hypoxemia)
04/2017 - 01/2016
3Hypertriglyceridemia
04/2016 - 08/2011
3Catheter-Related Infections
04/2016 - 01/2015
3Thrombosis (Thrombus)
01/2013 - 05/2002
2Pathologic Constriction (Stenosis)
02/2022 - 01/2021
2Death (Near-Death Experience)
01/2022 - 01/2022
2Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2022 - 04/2014

Drug/Important Bio-Agent (IBA)

10Epoprostenol (Prostacyclin)FDA LinkGeneric
11/2019 - 02/2005
9Pharmaceutical PreparationsIBA
01/2021 - 06/2002
7Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2022 - 08/2011
6Brain Natriuretic Peptide (Natrecor)FDA Link
01/2022 - 11/2008
6Biomarkers (Surrogate Marker)IBA
01/2019 - 01/2011
5voglibose (Basen)IBA
01/2022 - 07/2014
5Proteins (Proteins, Gene)FDA Link
12/2021 - 06/2002
5MonocrotalineIBA
01/2021 - 05/2015
5Eicosapentaenoic AcidIBA
06/2018 - 10/2014
4Sodium-Glucose Transport ProteinsIBA
03/2022 - 01/2019
4Nicorandil (SG 75)IBA
02/2021 - 06/2017
4LipidsIBA
01/2020 - 08/2011
4Angiotensin Receptor AntagonistsIBA
01/2019 - 10/2009
4Cystatin CIBA
09/2018 - 07/2013
4Carvedilol (Coreg)FDA LinkGeneric
08/2011 - 06/2002
4Anti-Arrhythmia AgentsIBA
08/2007 - 06/2002
3Sodium-Glucose Transporter 2 InhibitorsIBA
03/2022 - 01/2019
31,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA
01/2022 - 01/2019
3Bisoprolol (Concor)FDA LinkGeneric
11/2021 - 08/2011
3CalciumIBA
01/2021 - 10/2009
3LDL Lipoproteins (beta Lipoproteins)IBA
01/2020 - 10/2014
3pitavastatin (itavastatin)FDA Link
01/2020 - 01/2018
3LDL CholesterolIBA
01/2020 - 10/2014
3Isoproterenol (Isoprenaline)FDA LinkGeneric
01/2019 - 07/2006
3Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
01/2019 - 09/2004
3Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2019 - 09/2004
3Glycoside Hydrolase InhibitorsIBA
01/2019 - 07/2014
3Adrenal Cortex Hormones (Corticosteroids)IBA
10/2018 - 10/2007
3Imatinib Mesylate (Gleevec)FDA Link
04/2017 - 08/2012
3Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2017 - 10/2014
3SteroidsIBA
05/2015 - 09/2014
3Ezetimibe (Zetia)FDA Link
10/2014 - 08/2011
3Ion Channels (Ion Channel)IBA
12/2012 - 06/2004
3Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
11/2009 - 07/2004
3Sodium Channel BlockersIBA
04/2009 - 11/2003
3pilsicainideIBA
05/2008 - 11/2003
3Epinephrine (Adrenaline)FDA LinkGeneric
09/2004 - 06/2002
2Glucose (Dextrose)FDA LinkGeneric
03/2022 - 01/2022
2sacubitril and valsartan sodium hydrate drug combinationIBA
01/2022 - 01/2019
2omega-Chloroacetophenone (Mace)IBA
01/2022 - 01/2013
2Neprilysin (Neutral Endopeptidase)IBA
01/2022 - 01/2019
2Angiotensin Receptors (Angiotensin II Receptor)IBA
01/2022 - 01/2019
2AntioxidantsIBA
01/2022 - 08/2006
2DiureticsIBA
01/2022 - 01/2017

Therapy/Procedure

32Therapeutics
01/2022 - 02/2005
12Percutaneous Coronary Intervention
02/2022 - 11/2011
8Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
12/2017 - 05/2006
7Lung Transplantation
08/2017 - 09/2004
3Catheter Ablation
11/2019 - 04/2019
3Liver Transplantation
10/2019 - 01/2015
2Stents
02/2022 - 01/2013
2Drug Therapy (Chemotherapy)
01/2022 - 01/2020
2Length of Stay
01/2022 - 08/2019